CAPPS VICKIE L 4

4 · Janux Therapeutics, Inc. · Filed Jun 12, 2026

AI-generated summary of this filing

Updated Jun 13, 2026

Janux (JANX) Director Vickie Capps Receives RSU & Option Awards

What Happened

Janux Therapeutics director Vickie L. Capps received two non‑cash awards on 2026-06-11: 5,500 restricted stock units (RSUs) and a 15,500-share derivative award (an equity award/option). Both were granted at $0.00 (no cash purchase); total reported acquisition value = $0.

Key Details

Transaction date: 2026-06-11; Form 4 filed 2026-06-12 (appears timely).
Prices: both grants reported at $0.00 per share; reported acquisition amounts = $0.
Vesting/derivative notes:
- The 5,500 RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to continuous service (Footnote F1).
- The 15,500-share derivative award vests in equal monthly installments over the 12 months after June 11, 2026, and in any event will be fully vested by the next annual meeting, subject to continuous service (Footnote F2).
Shares owned after the transaction: not specified in the provided excerpt of the filing.
Filing timeliness: filing date is the day after the report date (not indicated as late).

Context

These are grants/awards (A) — not open‑market purchases or sales — so they reflect compensation/equity incentives rather than an insider buying or selling shares in the market.
The derivative award appears to be a time‑based grant (option or similar) that vests over 12 months; such awards are common for directors and typically require continued service to vest.

Form 4

Period: 2026-06-11

Director

Transactions

Award
Common Stock
[F1]
2026-06-11+5,500→ 79,598 total
Award
Stock Option (right to buy)
[F2]
2026-06-11+15,500→ 15,500 total
Exercise: $13.66Exp: 2036-06-10→ Common Stock (15,500 underlying)

Footnotes (2)

[F1]Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
[F2]The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

Signature

/s/ James Pennington, Attorney-in-Fact|2026-06-12

1 file